Positive Allosteric Modulators That Target NMDA Receptors Rectify Loss-of-function GRIN Variants Associated with Neurological and Neuropsychiatric Disorders

Overview

Journal Neuropharmacology

Specialties Neurology
Pharmacology

Date 2020 Jul 27

PMID 32712275

Citations 17

Authors

Weiting Tang

Ding Liu

Stephen F Traynelis

Hongjie Yuan

Affiliations

Soon will be listed here.

Abstract

N-methyl-d-aspartate receptors (NMDARs) mediate a slow component of excitatory synaptic transmission that plays important roles in normal brain function and development. A large number of disease-associated variants in the GRIN gene family encoding NMDAR GluN subunits have been identified in patients with various neurological and neuropsychiatric disorders. Many of these variants reduce the function of NMDARs by a range of different mechanisms, including reduced glutamate potency, reduced glycine potency, accelerated deactivation time course, decreased surface expression, and/or reduced open probability. We have evaluated whether three positive allosteric modulators of NMDAR receptor function (24(S)-hydroxycholesterol, pregnenolone sulfate, tobramycin) and three co-agonists (d-serine, l-serine, and d-cycloserine) can mitigate the diminished function of NMDARs harboring GRIN variants. We examined the effects of these modulators on NMDARs that contained 21 different loss-of-function variants in GRIN1, GRIN2A, or GRIN2B, identified in patients with epilepsy, intellectual disability, autism, and/or movement disorders. For all variants, some aspect of the reduced function was partially restored. Moreover, some variants showed enhanced sensitivity to positive allosteric modulators compared to wild type receptors. These results raise the possibility that enhancement of NMDAR function by positive allosteric modulators may be a useful therapeutic strategy.

Citing Articles

Spermidine Treatment Improves GRIN2B Loss-Of-Function, A Primary Disorder of Glutamatergic Neurotransmission.

Santos-Gomez A, Julia-Palacios N, Rejano-Bosch A, Mari-Vico R, Miguez-Cabello F, Masana M J Inherit Metab Dis. 2025; 48(2):e70015.

PMID: 40024627 PMC: 11872566. DOI: 10.1002/jimd.70015.

Ligand distances as key predictors of pathogenicity and function in NMDA receptors.

Montanucci L, Brunger T, Bhattarai N, Bosselmann C, Kim S, Allen J Hum Mol Genet. 2024; 34(2):128-139.

PMID: 39535073 PMC: 11780861. DOI: 10.1093/hmg/ddae156.

Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology.

Korinek M, Candelas Serra M, Abdel Rahman F, Dobrovolski M, Kuchtiak V, Abramova V Physiol Res. 2024; 73(Suppl 1):S413-S434.

PMID: 38836461 PMC: 11412357. DOI: 10.33549/physiolres.935346.

Spectrum of NMDA Receptor Variants in Neurodevelopmental Disorders and Epilepsy.

Gjerulfsen C, Krey I, Klockner C, Rubboli G, Lemke J, Moller R Methods Mol Biol. 2024; 2799:1-11.

PMID: 38727899 DOI: 10.1007/978-1-0716-3830-9_1.

Mechanistic and structural studies reveal NRAP-1-dependent coincident activation of NMDARs.

Goodell D, Whitby F, Mellem J, Lei N, Brockie P, Maricq A Cell Rep. 2024; 43(2):113694.

PMID: 38265937 PMC: 11531325. DOI: 10.1016/j.celrep.2024.113694.

References

Hansen K, Yi F, Perszyk R, Furukawa H, Wollmuth L, Gibb A . Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018; 150(8):1081-1105. PMC: 6080888. DOI: 10.1085/jgp.201812032. View

Amin J, Leng X, Gochman A, Zhou H, Wollmuth L . A conserved glycine harboring disease-associated mutations permits NMDA receptor slow deactivation and high Ca permeability. Nat Commun. 2018; 9(1):3748. PMC: 6138751. DOI: 10.1038/s41467-018-06145-w. View

Adams D, Yuan H, Holyoak T, Arajs K, Hakimi P, Markello T . Three rare diseases in one Sib pair: RAI1, PCK1, GRIN2B mutations associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA receptor glutamate insensitivity. Mol Genet Metab. 2014; 113(3):161-70. PMC: 4219933. DOI: 10.1016/j.ymgme.2014.04.001. View

Addis L, Virdee J, Vidler L, Collier D, Pal D, Ursu D . Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue. Sci Rep. 2017; 7(1):66. PMC: 5427847. DOI: 10.1038/s41598-017-00115-w. View

Balu D, Basu A, Corradi J, Cacace A, Coyle J . The NMDA receptor co-agonists, D-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. Neurobiol Dis. 2011; 45(2):671-82. PMC: 3259183. DOI: 10.1016/j.nbd.2011.10.006. View

Swanger S, Chen W, Wells G, Burger P, Tankovic A, Bhattacharya S . Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains. Am J Hum Genet. 2016; 99(6):1261-1280. PMC: 5142120. DOI: 10.1016/j.ajhg.2016.10.002. View

Horak M, Vlcek K, Petrovic M, Chodounska H, Vyklicky Jr L . Molecular mechanism of pregnenolone sulfate action at NR1/NR2B receptors. J Neurosci. 2004; 24(46):10318-25. PMC: 6730288. DOI: 10.1523/JNEUROSCI.2099-04.2004. View

Shin W, Kim K, Serraz B, Cho Y, Kim D, Kang M . Early correction of synaptic long-term depression improves abnormal anxiety-like behavior in adult GluN2B-C456Y-mutant mice. PLoS Biol. 2020; 18(4):e3000717. PMC: 7217483. DOI: 10.1371/journal.pbio.3000717. View

Allen A, Cossette P, Delanty N, Eichler E, Goldstein D, Han Y . De novo mutations in epileptic encephalopathies. Nature. 2013; 501(7466):217-21. PMC: 3773011. DOI: 10.1038/nature12439. View

10.

von Stulpnagel C, Ensslen M, Moller R, Pal D, Masnada S, Veggiotti P . Epilepsy in patients with GRIN2A alterations: Genetics, neurodevelopment, epileptic phenotype and response to anticonvulsive drugs. Eur J Paediatr Neurol. 2017; 21(3):530-541. DOI: 10.1016/j.ejpn.2017.01.001. View

11.

Platzer K, Yuan H, Schutz H, Winschel A, Chen W, Hu C . encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. J Med Genet. 2017; 54(7):460-470. PMC: 5656050. DOI: 10.1136/jmedgenet-2016-104509. View

12.

Farwell K, Shahmirzadi L, El-Khechen D, Powis Z, Chao E, Davis B . Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med. 2014; 17(7):578-86. DOI: 10.1038/gim.2014.154. View

13.

Bell S, Maussion G, Jefri M, Peng H, Theroux J, Silveira H . Disruption of GRIN2B Impairs Differentiation in Human Neurons. Stem Cell Reports. 2018; 11(1):183-196. PMC: 6067152. DOI: 10.1016/j.stemcr.2018.05.018. View

14.

Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N . Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol. 1994; 347(1):150-60. DOI: 10.1002/cne.903470112. View

15.

Hu C, Chen W, Myers S, Yuan H, Traynelis S . Human GRIN2B variants in neurodevelopmental disorders. J Pharmacol Sci. 2016; 132(2):115-121. PMC: 5125235. DOI: 10.1016/j.jphs.2016.10.002. View

16.

Masuko T, Kuno T, Kashiwagi K, Kusama T, Williams K, Igarashi K . Stimulatory and inhibitory properties of aminoglycoside antibiotics at N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1999; 290(3):1026-33. View

17.

Fernandez-Marmiesse A, Kusumoto H, Rekarte S, Roca I, Zhang J, Myers S . A novel missense mutation in GRIN2A causes a nonepileptic neurodevelopmental disorder. Mov Disord. 2018; 33(6):992-999. PMC: 6105539. DOI: 10.1002/mds.27315. View

18.

Lemke J, Lal D, Reinthaler E, Steiner I, Nothnagel M, Alber M . Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet. 2013; 45(9):1067-72. DOI: 10.1038/ng.2728. View

19.

XiangWei W, Kannan V, Xu Y, Kosobucki G, Schulien A, Kusumoto H . Heterogeneous clinical and functional features of GRIN2D-related developmental and epileptic encephalopathy. Brain. 2019; 142(10):3009-3027. PMC: 6763743. DOI: 10.1093/brain/awz232. View

20.

Ogden K, Chen W, Swanger S, McDaniel M, Fan L, Hu C . Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology. PLoS Genet. 2017; 13(1):e1006536. PMC: 5240934. DOI: 10.1371/journal.pgen.1006536. View